Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Piracetam wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Likely helps
4 of 5 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (3)
Outcomes where both Noopept and Piracetam have evidence — compare verdict strength side-by-side.
10-30mg daily in divided doses
Morning and early afternoon, Divided into 2-3 doses, Sublingual for faster onset
Noopept powder (sublingual) or capsules
1200-4800mg daily in divided doses
Divided into 2-3 doses, Morning and early afternoon, With a choline source
Piracetam powder or capsules
1-2 weeks
Acute to 1 week
Ongoing
With higher doses
2-4 weeks
1-2 weeks
Ongoing
First few days
Novel Technologies for Dipeptide Drugs Design and their Implantation
Current pharmaceutical design (2018) · Systematic review
The latter usually corresponds to a beta-turn of some regulatory peptide.
Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation
Journal of biomedical science (2014) · Observational
Taken together, these data provide evidence that novel cognitive enhancer noopept protects PC12 cell against deleterious actions of Aβ through inhibiting the oxidative damage and calcium overload as well as suppressing the mitochondrial apoptotic pathway.
Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin
Neuroscience and behavioral physiology (2009) · Observational
Clinical trial examining Noopept efficacy
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Piracetam for reducing the incidence of painful sickle cell disease crises
The Cochrane database of systematic reviews (2016) · Meta analysis · n=169
Although there was no significant difference between the piracetam and placebo periods for the number of days of hospitalisation (P = 0.87) in one trial, inconsistencies in the criteria necessary for hospitalisation during sickle crises did not permit accurate conclusions to be drawn.
Treatment Efficacy of Pharmacotherapies for Frontotemporal Dementia: A Network Meta-Analysis of Randomized Controlled Trials
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry (2023) · Meta analysis · n=243
Compared with placebo, high-dose oxytocin (72 international units) was associated with the greatest improvement in patients' neuropsychiatric symptoms (SMD = -1.17, 95% CIs = -2.25 to -0.08, z = -2.10, p = 0.035).
Based on RCT with n=60 showing MMSE improvements after 2 months. Most studies lack placebo controls and have small sample sizes. Effectiveness may be overestimated due to study limitations.
Based on meta-analysis of 1002 stroke patients, but showed non-significant increase in death at one month. Evidence is limited and mixed. Conservative effectiveness estimates due to safety concerns.
AI-estimated from published studies. Interpret as directional guidance.
Piracetam has a higher evidence score (4.5/10 vs 4/10) and wins in 3 of 3 categories.
Both Noopept and Piracetam score equally (75) for sharpen focus.
No known interactions between Noopept and Piracetam have been documented in our database. However, always consult a healthcare provider before combining supplements.